EyePoint Pharmaceuticals has successfully concluded Phase III enrollment for Duravyu (EYP-1901), a groundbreaking sustained-release therapy for wet Age-related Macular Degeneration (wet AMD). With over 400 subjects across the pivotal LUCIA and LUGANO trials

Learn how novel approaches to clinical trial design, including integrated models and adaptive methods, are addressing the high costs and inefficiency of traditional drug development, particularly in Phase II and III trials, to reduce attrition rates and increase productivity.

Explore the Hepatitis B global clinical trial landscape in 2025 with insights into novel therapies, ongoing research for a functional cure, emerging biomarkers, and investment trends from a new report by Novotech